Sareum Holdings plc (RYH0)

Overview

Sareum Holdings plc is a clinical stage small molecule drug development company focused on the discovery and development of novel therapeutic drugs for the treatment of cancer and autoimmune diseases. Utilizing its proprietary Sareum Kinase Inhibitor Library drug discovery platform, the company advances its mission by developing small molecule therapeutic drugs. Established in 2004 and headquartered in Cambridge, the United Kingdom, Sareum Holdings plc has positioned itself as a key player in the biopharmaceutical field with its advanced clinical and preclinical stage products aimed at addressing unmet medical needs in cancer and autoimmune disease treatment.

Products and Services

• SDC-1801

SDC-1801 is a TYK2/JAK1 inhibitor currently in Phase 1a clinical trials aimed at treating autoimmune diseases. This product represents Sareum's commitment to leveraging its drug development capabilities to address the complex challenges of autoimmune disorders. By targeting specific kinases involved in the signaling pathways of the immune system, SDC-1801 has the potential to offer a new therapeutic approach for patients suffering from these conditions.

• SDC-1802

SDC-1802 is another TYK2/JAK1 inhibitor but is in the preclinical stage of development. It is designed for applications in cancer and cancer immunotherapy. This investigational treatment embodies the company’s efforts to expand the application of its kinase inhibition technology beyond autoimmune diseases, aiming to exploit the immune system's capability to fight cancer by selectively inhibiting kinases that are critical for cancer cell survival and immune evasion.

• SRA737

SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, has completed Phase II clinical trials. It targets cancer cell replication and DNA damage repair mechanisms. By focusing on Chk1, SRA737 aims to exploit a vulnerability in cancer cells' ability to replicate and repair DNA damage, thereby providing a novel approach to cancer therapy. The completion of Phase II trials marks a significant milestone in its development, highlighting its potential as a promising therapy for cancer patients.